Kidney Sarcoma: Comprehensive Disease-Characteristics Report

Evidence cut-off: December 2024, with emphasis on 2023–2024 literature. Scope: “Kidney sarcoma” is an umbrella category rather than one molecular disease. Evidence is dominated by retrospective registries, small series, and extrapolation from histology-matched soft-tissue sarcoma (STS); prospective kidney-sarcoma-specific trials are essentially absent.

Executive summary

Primary renal sarcomas are malignant mesenchymal tumors arising in the kidney, renal capsule, sinus, vessels, or supporting soft tissue. They must not be conflated with sarcomatoid renal-cell carcinoma, an epithelial carcinoma showing mesenchymal-appearing dedifferentiation, or with clear cell sarcoma of kidney (CCSK), a specific pediatric tumor. The strongest contemporary epidemiologic study—1,279 adults in SEER/NCDB, published May 2024—found an age-adjusted incidence of 0.53 per million persons/year, accounting for 0.25% of renal malignancies, but encompassing 43 histotypes. Median overall survival was approximately 25 months. At presentation, 33.3% were T3, 14.2% T4, and 29.1% metastatic; 81.6% underwent surgery. Histotype, stage, metastasis, necrosis, surgical margin, age, sex, and comorbidity materially affected survival. (uhlig2024epidemiologytreatmentand pages 1-2, uhlig2024epidemiologytreatmentand pages 5-7, uhlig2024epidemiologytreatmentand pages 9-10)

The authoritative interpretation is therefore histology-first management at a sarcoma reference center, not uniform treatment as kidney cancer. The 2024 investigators concluded that renal sarcomas “include 43 histiotypes with distinct epidemiology, clinical presentation, outcomes and sensitivity to systemic therapy,” and observed that real-world care frequently followed renal-cancer rather than STS principles. (uhlig2024epidemiologytreatmentand pages 1-2, uhlig2024epidemiologytreatmentand pages 7-9)

1. Disease information

Definition, category, and identifiers

• Preferred name: kidney sarcoma; common clinical synonym: primary renal sarcoma.
• Category: rare malignant mesenchymal neoplasm of the kidney; an anatomic umbrella containing multiple WHO-defined STS histotypes.
• MONDO: MONDO:0002930 — kidney sarcoma. Open Targets recognizes it as a distinct disease entity. (OpenTargets Search: kidney sarcoma)
• Related but distinct: MONDO:0005006 — clear cell sarcoma of kidney; MONDO:0010434 — synovial sarcoma. (OpenTargets Search: kidney sarcoma)
• MeSH: generally indexed through Sarcoma, Kidney Neoplasms, and the specific histotype; a unique kidney-sarcoma MeSH heading is not consistently used.
• ICD-10-CM: no histologically precise single code. Registries commonly combine site C64.-, malignant neoplasm of kidney except renal pelvis, with an ICD-O-3 morphology code such as leiomyosarcoma 8890/3, angiosarcoma 9120/3, synovial sarcoma 9040–9043/3, or Ewing sarcoma 9260/3.
• ICD-11: coded by malignant kidney site plus morphology/histopathology; local coding systems should retain both dimensions.
• OMIM/Orphanet: no single inherited-disorder entry adequately represents the heterogeneous adult umbrella. Individual molecular subtypes may have separate disease records.

Important exclusions: Sarcomatoid RCC is not a sarcoma; it can occur in most RCC subtypes, represents about 4% of all RCC but approximately 20% of metastatic RCC, and is WHO/ISUP grade 4. Its biology and checkpoint-based RCC treatment differ from primary renal sarcoma. CCSK is likewise a distinct childhood renal tumor with BCOR-family biology. (OpenTargets Search: kidney sarcoma)

Evidence provenance: The principal quantitative evidence is aggregated disease-level registry data, not individual EHR records. SEER and NCDB provide de-identified population/hospital-level observations; case reports and institutional series contribute individual-patient evidence. (uhlig2024epidemiologytreatmentand pages 1-2, uhlig2024epidemiologytreatmentand pages 9-10)

2. Etiology, risk, and protective factors

Causal factors

Most cases are sporadic cancers caused by acquired somatic alterations. There is no single causal gene for “kidney sarcoma.” Instead, causal events depend on histotype: SS18::SSX in synovial sarcoma, EWSR1::FLI1 or related ETS fusion in Ewing sarcoma, BCOR internal tandem duplication or YWHAE::NUTM2 in CCSK, and EWSR1::CREB3L1 in sclerosing epithelioid fibrosarcoma. These are generally tumor-defining somatic rearrangements, not inherited alleles. (OpenTargets Search: kidney sarcoma, bradford2020primaryrenalewing pages 7-7, baydar2015primarysclerosingepithelioid pages 12-12)

Risk factors

• Age and sex: these are demographic associations, not proven causes. Adult renal sarcoma had median age about 60 years; renal leiomyosarcoma (LMS) occurred at a median of 62, whereas renal PNET/Ewing-family tumors occurred much younger, around 33 in the registry. LMS was female-predominant (male:female ratio 0.46), while angiosarcoma was male-predominant (3.82). (uhlig2024epidemiologytreatmentand pages 3-5, uhlig2024epidemiologytreatmentand pages 7-9)
• Ionizing radiation and hereditary cancer predisposition: recognized general STS risks, but kidney-specific attributable risks have not been quantified in modern cohorts.
• Smoking, obesity, hepatitis C, asbestos, VHL, Birt–Hogg–Dubé, and hereditary papillary RCC: these are established or proposed renal carcinoma associations and should not be automatically assigned to primary renal sarcoma. A renal-tumor educational review lists them together, but it does not establish histotype-specific causality; this is a key evidence-quality limitation. (mohd2022etiologiesgrossappearance pages 9-10)
• Infectious causes: none established for conventional primary renal sarcoma. EBV-associated smooth-muscle tumors may occur under profound immunosuppression, but they are a separate clinicopathologic context.
• Gene–environment interaction: no replicated renal-sarcoma-specific G×E interaction has been demonstrated.

Protective factors

No genetic variant, diet, drug, lifestyle behavior, vaccine, or occupational intervention has been shown specifically to prevent primary renal sarcoma. General avoidance of unnecessary ionizing radiation and tobacco is reasonable health policy but is not evidence-based kidney-sarcoma prophylaxis.

3. Phenotypes

Clinical manifestations reflect an enlarging renal/retroperitoneal mass and metastatic spread. Frequencies are incompletely reported because histotypes are rare and registry symptom fields are limited.

• Renal/abdominal mass — usually adult or adolescent onset according to subtype; often large and progressive. Suggested HPO: HP:0009726, renal neoplasm; HP:0031500, abdominal mass.
• Flank or abdominal pain — variable, progressive as capsule or adjacent structures are involved. HPO: HP:0031605, flank pain; HP:0002027, abdominal pain.
• Hematuria — intermittent gross or microscopic bleeding when collecting-system or vascular structures are invaded. HPO: HP:0000790, hematuria.
• Constitutional effects: weight loss, fatigue, fever, anorexia, or anemia in advanced disease. Suggested HPO: HP:0001824, weight loss; HP:0012378, fatigue; HP:0001945, fever; HP:0001903, anemia.
• Metastatic manifestations: cough/dyspnea from pulmonary metastases and bone pain/pathologic fracture from osseous spread. Among metastatic adult cases, lung involvement was reported in 68% and bone involvement in 41.2%. (uhlig2024epidemiologytreatmentand pages 3-5)
• Laboratory abnormalities: anemia, hematuria, impaired renal function, or elevated inflammatory indices can occur, but none is sensitive or specific. There is no validated serum tumor marker.

Severity is highly variable but frequently substantial: median tumor diameter was approximately 10 cm, and almost half of registry patients had T3–T4 disease. Pain, cancer-related fatigue, loss of renal function after nephrectomy, systemic-therapy toxicity, fear of recurrence, and metastatic disability impair quality of life. No kidney-sarcoma-specific EQ-5D, SF-36, or PROMIS reference dataset was identified. (uhlig2024epidemiologytreatmentand pages 1-2, uhlig2024epidemiologytreatmentand pages 7-9)

4. Genetic and molecular information

Table: This table summarizes the major histologic entities that present as primary renal sarcoma or are commonly confused with it, highlighting subtype-defining molecular alterations, practical diagnostic markers, behavior, and treatment logic. It is useful for distinguishing the heterogeneous adult renal sarcoma umbrella from specific fusion-defined and pediatric renal tumor entities.

Interpretation of variants

These rearrangements/ITDs are somatic structural oncogenic events, generally absent from population germline databases; therefore, gnomAD allele frequency and Mendelian carrier frequency are not meaningful. They should be reported under AMP/ASCO/CAP somatic-oncology conventions, not assigned germline ACMG pathogenicity without separate constitutional testing.

• Synovial sarcoma: t(X;18) produces SS18::SSX1/SSX2, replacing native SS18 in the BAF/SWI–SNF chromatin-remodeling complex and reprogramming enhancer accessibility. Open Targets strongly associates SS18, SSX1, and SSX2 with synovial sarcoma. (OpenTargets Search: kidney sarcoma)
• Ewing sarcoma: usually EWSR1::FLI1, an aberrant ETS transcription factor that rewires enhancer activity, cell-cycle programs, differentiation, and invasion. Renal disease shares the canonical molecular lesion but has disproportionately aggressive presentation. (bradford2020primaryrenalewing pages 7-7, bradford2020primaryrenalewing pages 5-7)
• CCSK: most tumors contain a BCOR exon-15 internal tandem duplication; a smaller, usually mutually exclusive group carries YWHAE::NUTM2. NTRK3 transcription/protein overexpression is reported across BCOR-family tumors, including CCSK, but is not equivalent to an actionable NTRK fusion. (OpenTargets Search: kidney sarcoma)
• SEF: reported renal tumors were MUC4-positive and carried EWSR1::CREB3L1. One of two patients had disseminated disease at diagnosis. (baydar2015primarysclerosingepithelioid pages 12-12)
• LMS: usually has a complex genome rather than one defining fusion; disruption of TP53/RB1/PTEN-associated cell-cycle and survival control is biologically plausible across LMS. Renal-specific comprehensive genomic series remain scarce.

No validated kidney-sarcoma modifier genes, protective alleles, founder variants, germline mosaicism, anticipation, or carrier frequency are known. Constitutional testing is appropriate only when age, multiple tumors, family history, or pathology suggests a predisposition syndrome.

5. Environmental information

There is no reproducible renal-sarcoma-specific association with smoking, alcohol, diet, exercise, air pollution, pesticides, or occupational agents. Prior radiotherapy is a recognized general cause of radiation-induced STS after latency, but a primary renal sarcoma should be labeled radiation-associated only when accepted temporal and anatomic criteria are met. No bacterial, viral, fungal, or parasitic cause applies to the conventional disease. Prevention databases should therefore record most proposed exposures as unknown/not established, not negative causal facts.

6. Mechanism and pathophysiology

Causal chain

1. Initiation: a renal mesenchymal/progenitor, smooth-muscle, vascular-endothelial, or poorly differentiated precursor acquires a subtype-defining fusion or complex tumor-suppressor damage.
2. Upstream transcriptional/chromatin dysregulation: fusion proteins such as SS18::SSX and EWSR1::FLI1 alter chromatin occupancy and transcription; BCOR lesions disturb Polycomb-associated repression.
3. Downstream processes: sustained proliferation, failed differentiation, apoptosis evasion, angiogenesis, extracellular-matrix remodeling, invasion, and metastatic dissemination.
4. Tissue injury: expansile growth causes compression and ischemia; invasion produces hemorrhage, necrosis, collecting-system bleeding, and replacement of renal parenchyma.
5. Clinical expression: mass, pain, hematuria, anemia, loss of renal function, and lung/bone/nodal metastases.

Suggested GO biological processes include GO:0007049 cell cycle, GO:0008283 cell population proliferation, GO:0006915 apoptotic process, GO:0001525 angiogenesis, GO:0030198 extracellular matrix organization, GO:0007155 cell adhesion, GO:0016477 cell migration, and GO:0006355 regulation of DNA-templated transcription. Relevant cell types include CL:0000192 smooth muscle cell for LMS, CL:0000115 endothelial cell for angiosarcoma, CL:0000057 fibroblast for fibroblastic sarcomas, and an incompletely resolved primitive mesenchymal progenitor for fusion-driven round-cell tumors.

Molecular profiling and advanced technologies

No TCGA-scale, kidney-sarcoma-specific single-cell, spatial-transcriptomic, proteomic, metabolomic, lipidomic, or integrated multi-omics atlas was identified. Existing evidence comes mainly from bulk tumor sequencing, fusion assays, IHC, and histotype-level sarcoma datasets. This lack of renal-specific molecular profiling is a major research gap and precludes defining a universal metabolic or immune signature.

7. Anatomical structures affected

• Primary organ: kidney — suggested UBERON:0002113.
• Potential sites of origin: renal capsule, parenchymal interstitium, renal sinus, pelvis-adjacent soft tissue, and renal vascular smooth muscle/endothelium.
• Local extension: perinephric fat, Gerota fascia, renal vein/inferior vena cava, adrenal gland, psoas, bowel, pancreas, spleen, liver, or abdominal wall depending on side and size.
• Secondary organs: lung and bone predominate; regional lymph nodes are particularly important in renal Ewing sarcoma. Renal ESFT nodal disease occurred in approximately 24%, compared with 3.2% in skeletal ESFT. (bradford2020primaryrenalewing pages 5-7)
• Laterality: generally unilateral; no consistent right/left preference is established.
• Subcellular compartments: nucleus/chromatin for fusion-driven transcriptional mechanisms (GO:0005634 nucleus, GO:0000785 chromatin); cytoskeleton/contractile apparatus in LMS; endothelial junctions and extracellular matrix in angiosarcoma.

8. Temporal development

Adult LMS and angiosarcoma usually develop insidiously in middle-to-late adulthood; renal synovial and Ewing sarcomas affect younger patients; CCSK and rhabdoid tumor are chiefly pediatric. The course is progressive rather than episodic. Localized disease may enter treatment-induced remission after complete resection, but high-grade tumors can recur locally or hematogenously years later.

Renal Ewing sarcoma is often rapidly progressive: pooled evidence found 53.2% metastatic at diagnosis, substantially exceeding the general Ewing population. In the reported pediatric/young-adult institutional series, five of seven patients relapsed after initial remission. (bradford2020primaryrenalewing pages 7-7, bradford2020primaryrenalewing pages 5-7)

Staging should use the applicable AJCC soft-tissue sarcoma site/stage framework, supplemented by FNCLCC grade where valid for the histotype. CCSK, rhabdoid tumor, and Ewing sarcoma follow pediatric/diagnosis-specific staging and response systems rather than adult retroperitoneal STS rules.

9. Inheritance and population

The overall incidence was 0.53 cases per million persons annually during 2004–2016, stable over time (AAPC 0.7%; p=0.6). LMS alone occurred at 0.14/million and malignant rhabdoid tumor at 0.06/million. (uhlig2024epidemiologytreatmentand pages 1-2)

No conventional inheritance pattern, penetrance, anticipation, carrier state, founder effect, or consanguinity relationship applies to the umbrella diagnosis. Most defining alterations are acquired in the tumor. The national cohort showed marked sex variation by histotype rather than one universal sex ratio. No robust ethnicity-specific or geographic concentration is established; apparent differences are vulnerable to small numbers and registry ascertainment. (uhlig2024epidemiologytreatmentand pages 3-5)

10. Diagnostics

Recommended workflow

1. Imaging: multiphasic contrast CT or MRI of the abdomen/pelvis to define renal origin, local invasion, vessel involvement, and resectability; CT chest for pulmonary staging. MRI is especially useful for venous thrombus and soft-tissue planes. PET/CT is selective, not a substitute for chest/abdominal staging.
2. Multidisciplinary review: radiology, urologic/sarcoma surgery, medical and radiation oncology, and specialist sarcoma pathology before definitive treatment.
3. Biopsy: image-guided coaxial core biopsy along a tract that can be removed or safely encompassed. Upfront surgery may be reasonable for a resectable renal mass when management would not change, but biopsy is particularly valuable for unresectable/metastatic disease or when neoadjuvant therapy is contemplated.
4. Histology/IHC: determine spindle, round-cell, pleomorphic, vascular, or epithelioid pattern; assess mitoses, necrosis, grade, and margins. A practical panel may include pancytokeratin/EMA and PAX8 to exclude carcinoma; SMA/desmin/h-caldesmon for LMS; ERG/CD31 for angiosarcoma; S100/SOX10; myogenin/MyoD1; CD99/NKX2.2; TLE1 and SS18–SSX; BCOR; INI1; MDM2; STAT6; and MUC4 according to morphology.
5. Molecular confirmation: targeted RNA sequencing is preferred for suspected fusion sarcoma; alternatives include break-apart FISH, RT-PCR, or fusion-specific IHC. DNA NGS is useful for complex-genome tumors and actionable alterations but can miss RNA-level fusions.

Differential diagnosis

The essential exclusions are sarcomatoid RCC, collecting-duct/urothelial carcinoma, Wilms tumor, CCSK, malignant rhabdoid tumor, angiomyolipoma/PEComa, solitary fibrous tumor, retroperitoneal liposarcoma secondarily involving kidney, metastasis, lymphoma, and benign leiomyoma. Renal sarcoma and retroperitoneal sarcoma can be difficult to distinguish anatomically; expert radiology and examination of the resection relationship to renal parenchyma/capsule are required. (uhlig2024epidemiologytreatmentand pages 9-10)

No blood/urine biomarker, liquid-biopsy assay, WES/WGS screen, CMA, karyotype, mitochondrial assay, or repeat-expansion test is recommended for routine asymptomatic screening. Germline panel/WES is reserved for clinical suspicion of inherited predisposition.

11. Outcome and prognosis

Across the 2024 adult cohort, median OS was 25 months, although outcomes differed greatly by histotype and stage. Angiosarcoma had worse survival than LMS (HR 2.42). Independently favorable factors included younger age, female sex, lower comorbidity, lower T stage, negative margins, no necrosis, no distant metastasis, and LMS histology. (uhlig2024epidemiologytreatmentand pages 1-2, uhlig2024epidemiologytreatmentand pages 5-7)

Positive margins occurred in 21.3% overall and 40.6% of T4 resections, emphasizing the importance of planned en-bloc surgery. Distant disease was present in approximately 29–32%. (uhlig2024epidemiologytreatmentand pages 3-5, uhlig2024epidemiologytreatmentand pages 5-7)

For renal Ewing sarcoma, localized survival was reported at approximately 55%, while metastatic and nodal disease predicted inferior OS. Pulmonary-only metastasis generally fares better than bone/bone-marrow disease, but renal-primary outcomes remain worse than conventional localized Ewing benchmarks. (bradford2020primaryrenalewing pages 7-7, bradford2020primaryrenalewing pages 5-7)

Functional morbidity includes nephrectomy-related reduction in renal reserve, chronic kidney disease risk, chemotherapy cardiotoxicity/myelosuppression, ifosfamide nephrotoxicity/Fanconi syndrome, radiation injury, chronic pain, and disability from metastatic disease. Kidney-specific quality-of-life and disability-adjusted-life-year estimates are unavailable.

12. Treatment and real-world implementation

Localized adult disease

Complete en-bloc resection with microscopically negative margins (R0) is the only established curative foundation—usually radical nephrectomy, occasionally organ-sparing resection for carefully selected small lesions. In the national cohort, 81.6% underwent resection and 69.3% underwent radical/total nephrectomy. Suggested NCIt terms: Radical Nephrectomy, Partial Nephrectomy, Surgical Resection, and Metastasectomy. (uhlig2024epidemiologytreatmentand pages 1-2, uhlig2024epidemiologytreatmentand pages 3-5)

Routine lymphadenectomy is not supported for all adult STS histotypes, although suspicious nodes should be removed and nodal evaluation is particularly relevant to renal Ewing sarcoma. Radiotherapy may be considered for close/positive margins, unresectable local disease, palliation, or selected radiosensitive histotypes, but renal-adjacent bowel/liver/spinal cord and the remaining kidney constrain dose.

Systemic therapy

Treatment should follow histotype-specific STS practice:

• Adult LMS/undifferentiated or pleomorphic STS: doxorubicin, doxorubicin–ifosfamide when tumor shrinkage is critical, or gemcitabine–docetaxel; later options may include pazopanib, trabectedin, dacarbazine, or eribulin according to histology, prior therapy, jurisdiction, and patient fitness.
• Renal synovial sarcoma: comparatively ifosfamide-sensitive; anthracycline/ifosfamide-based therapy is commonly used for high-risk or advanced disease.
• Renal Ewing sarcoma: interval-compressed VDC/IE—vincristine/doxorubicin/cyclophosphamide alternating with ifosfamide/etoposide—plus nephrectomy/local control and completion chemotherapy. The review describes 8–12 weeks of preoperative chemotherapy followed by negative-margin surgery and selective postoperative radiation. Suggested NCIt terms include the individual agents, Combination Chemotherapy, External Beam Radiation Therapy, and Nephrectomy. (bradford2020primaryrenalewing pages 7-7)
• CCSK/rhabdoid tumor: pediatric cooperative-group protocols combining nephrectomy, intensive multiagent chemotherapy, and stage/risk-directed radiotherapy; these should not be treated as adult LMS.
• Angiosarcoma: taxane- or anthracycline-based therapy and selected antiangiogenic approaches are extrapolated from nonrenal angiosarcoma.

In real-world renal sarcoma, systemic therapy was used in only 16.1% of localized cases, 39.8% of T4 cases, and 54.6% of metastatic cases; 93.3% of systemic treatment was adjuvant and only 4.6% neoadjuvant. Primary-site radiotherapy was used in 5.2%. Registry associations suggested benefit from systemic treatment in LMS, angiosarcoma, and clear-cell sarcoma, but confounding by indication prevents causal interpretation. (uhlig2024epidemiologytreatmentand pages 5-7, uhlig2024epidemiologytreatmentand pages 7-9)

Targeted, immune, cellular, and experimental treatment

Broad DNA/RNA profiling is reasonable in advanced disease to identify rare actionable fusions or mutations. Open Targets links kidney sarcoma chiefly to chemotherapy targets such as TOP2A and tubulins, reflecting anthracycline and microtubule-directed regimens rather than kidney-specific dependencies. In synovial sarcoma, SS18/SSX are causal but not yet routine drug targets. (OpenTargets Search: kidney sarcoma)

Checkpoint inhibitors have no established kidney-sarcoma-wide role; efficacy is histotype-dependent and generally lower in fusion-driven, low-mutation-burden tumors. Do not extrapolate the marked checkpoint sensitivity of sarcomatoid RCC to true renal sarcoma.

Relevant basket or adjacent trials identified include NCT02795819 (AR-42 plus pazopanib; phase I, terminated after six participants), NCT03798106 (pazopanib plus durvalumab in metastatic STS; phase II, completed), and NCT06444880 (ubamatamab ± cemiplimab in MUC16-expressing SMARCB1-deficient malignancies; phase II, active-not-recruiting). These are not proof of efficacy specifically in primary renal sarcoma.

13. Prevention

• Primary prevention: no disease-specific intervention or vaccine.
• Secondary prevention: no population screening; rarity makes ultrasound, CT, urine, or molecular screening unjustified in average-risk asymptomatic people.
• High-risk genetics: counseling and syndrome-specific surveillance only when a constitutional predisposition is clinically demonstrated; no kidney-sarcoma-specific carrier screening, prenatal test, or preimplantation-testing recommendation exists.
• Tertiary prevention: expert surgery, preservation of contralateral renal function, avoidance of nephrotoxins, rehabilitation, thrombosis/pain/nutrition management, and structured surveillance to detect resectable recurrence.
• Follow-up: chest and abdominal cross-sectional imaging should be individualized by grade, histotype, stage, and treatment; high-grade disease requires closer early follow-up because lung relapse is common.

14. Other species and natural disease

Naturally occurring primary renal LMS has been reported in domestic cats (NCBI Taxon 9685; Felis catus), but evidence consists primarily of isolated veterinary case reports. Similar renal spindle-cell morphology and smooth-muscle immunophenotype provide comparative-pathology interest, not a validated translational model. Breed predisposition and Vertebrate Breed Ontology associations are unknown. Sporadic renal sarcomas also occur in dogs, but robust incidence and molecular-concordance studies are lacking. There is no zoonotic or cross-species transmission.

15. Model organisms and experimental systems

No single model captures the 43-histotype renal-sarcoma umbrella. Models are subtype-specific:

• human cell lines and 2-D/3-D cultures;
• subcutaneous or renal-subcapsular xenografts in immunodeficient mice;
• patient-derived xenografts/orthotopic xenografts;
• fusion-driven Ewing or synovial sarcoma genetically engineered mouse models;
• zebrafish embryo and chick chorioallantoic-membrane xenografts for rapid invasion and drug-response studies.

Renal-subcapsular xenografting supplies a vascular microenvironment and allows growth/metastasis studies, but implantation site does not prove renal cell of origin. Xenografts retain human tumor genetics but lack an intact human immune system; GEMMs model initiation and immune interactions but can underrepresent human genomic complexity and metastasis. Accordingly, these systems support mechanism and drug discovery at the histotype level, not validation of one universal kidney-sarcoma mechanism.

Evidence appraisal and research priorities

The 2024 SEER/NCDB analysis is the best contemporary population evidence, but it lacked treatment-regimen detail, mutation status, complete grade information, and robust radiotherapy numbers. Its treatment-survival associations are retrospective. The renal Ewing literature is larger than that for most subtypes but remains vulnerable to publication bias. (uhlig2024epidemiologytreatmentand pages 9-10, bradford2020primaryrenalewing pages 5-7)

Priority needs are prospective international registration with central pathology review; mandatory RNA-fusion and DNA profiling; histotype-stratified treatment data; renal-specific organoid/PDX models; single-cell and spatial profiling; circulating-tumor-DNA studies; patient-reported outcomes; and trials that enroll by molecular histotype rather than merely renal site.

Selected recent and authoritative sources

1. Uhlig J, et al. “Epidemiology, treatment and outcomes of primary renal sarcomas in adult patients.” Scientific Reports. Published May 2024. DOI/URL: https://doi.org/10.1038/s41598-024-60174-8. Abstract quotation: “Accounting for 0.25% of renal malignancies, renal sarcomas include 43 histiotypes with distinct epidemiology, clinical presentation, outcomes and sensitivity to systemic therapy.” (uhlig2024epidemiologytreatmentand pages 1-2)
2. Bradford K, et al. “Primary Renal Ewing Sarcoma in Children and Young Adults.” Journal of Pediatric Hematology/Oncology. Published April 2020. DOI/URL: https://doi.org/10.1097/MPH.0000000000001804. Abstract quotation: “primary renal ESFT presentations seem to be more aggressive and have worse outcomes.” (bradford2020primaryrenalewing pages 7-7, bradford2020primaryrenalewing pages 5-7)
3. Baydar DE, et al. “Primary sclerosing epithelioid fibrosarcoma of kidney…” Diagnostic Pathology. Published October 2015. DOI/URL: https://doi.org/10.1186/s13000-015-0420-z. The reported renal tumors showed MUC4 expression and EWSR1–CREB3L1 fusion. (baydar2015primarysclerosingepithelioid pages 12-12)
4. Open Targets Platform, kidney sarcoma MONDO:0002930. Disease–target evidence includes chemotherapy-associated TOP2A/tubulin targets and subtype-defining SS18/SSX associations for synovial sarcoma: https://platform.opentargets.org/. (OpenTargets Search: kidney sarcoma)

References

1. (uhlig2024epidemiologytreatmentand pages 1-2): Johannes Uhlig, Annemarie Uhlig, Hari Deshpande, Philipp Ströbel, Lutz Trojan, Joachim Lotz, Michael Hurwitz, Omeed Hafez, Peter Humphrey, Viktor Grünwald, and Hyun S. Kim. Epidemiology, treatment and outcomes of primary renal sarcomas in adult patients. Scientific Reports, May 2024. URL: https://doi.org/10.1038/s41598-024-60174-8, doi:10.1038/s41598-024-60174-8. This article has 7 citations and is from a peer-reviewed journal.

2. (uhlig2024epidemiologytreatmentand pages 5-7): Johannes Uhlig, Annemarie Uhlig, Hari Deshpande, Philipp Ströbel, Lutz Trojan, Joachim Lotz, Michael Hurwitz, Omeed Hafez, Peter Humphrey, Viktor Grünwald, and Hyun S. Kim. Epidemiology, treatment and outcomes of primary renal sarcomas in adult patients. Scientific Reports, May 2024. URL: https://doi.org/10.1038/s41598-024-60174-8, doi:10.1038/s41598-024-60174-8. This article has 7 citations and is from a peer-reviewed journal.

3. (uhlig2024epidemiologytreatmentand pages 9-10): Johannes Uhlig, Annemarie Uhlig, Hari Deshpande, Philipp Ströbel, Lutz Trojan, Joachim Lotz, Michael Hurwitz, Omeed Hafez, Peter Humphrey, Viktor Grünwald, and Hyun S. Kim. Epidemiology, treatment and outcomes of primary renal sarcomas in adult patients. Scientific Reports, May 2024. URL: https://doi.org/10.1038/s41598-024-60174-8, doi:10.1038/s41598-024-60174-8. This article has 7 citations and is from a peer-reviewed journal.

4. (uhlig2024epidemiologytreatmentand pages 7-9): Johannes Uhlig, Annemarie Uhlig, Hari Deshpande, Philipp Ströbel, Lutz Trojan, Joachim Lotz, Michael Hurwitz, Omeed Hafez, Peter Humphrey, Viktor Grünwald, and Hyun S. Kim. Epidemiology, treatment and outcomes of primary renal sarcomas in adult patients. Scientific Reports, May 2024. URL: https://doi.org/10.1038/s41598-024-60174-8, doi:10.1038/s41598-024-60174-8. This article has 7 citations and is from a peer-reviewed journal.

5. (OpenTargets Search: kidney sarcoma): Open Targets Query (kidney sarcoma, 50 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

6. (bradford2020primaryrenalewing pages 7-7): Kathryn Bradford, Alexander Nobori, Brittany Johnson, Wendy Allen-Rhoades, Bindi Naik-Mathuria, Eduard H. Panosyan, Moran Gotesman, Joseph Lasky, Jerry Cheng, Alan Ikeda, Jeffrey Goldstein, Arun Singh, and Noah Federman. Primary renal ewing sarcoma in children and young adults. Journal of Pediatric Hematology/Oncology, 42:474-481, Apr 2020. URL: https://doi.org/10.1097/mph.0000000000001804, doi:10.1097/mph.0000000000001804. This article has 24 citations.

7. (baydar2015primarysclerosingepithelioid pages 12-12): Dilek Ertoy Baydar, Kemal Kosemehmetoglu, Oguz Aydin, Julia A. Bridge, Berrin Buyukeren, and Fazil Tuncay Aki. Primary sclerosing epithelioid fibrosarcoma of kidney with variant histomorphologic features: report of 2 cases and review of the literature. Diagnostic Pathology, Oct 2015. URL: https://doi.org/10.1186/s13000-015-0420-z, doi:10.1186/s13000-015-0420-z. This article has 35 citations and is from a peer-reviewed journal.

8. (uhlig2024epidemiologytreatmentand pages 3-5): Johannes Uhlig, Annemarie Uhlig, Hari Deshpande, Philipp Ströbel, Lutz Trojan, Joachim Lotz, Michael Hurwitz, Omeed Hafez, Peter Humphrey, Viktor Grünwald, and Hyun S. Kim. Epidemiology, treatment and outcomes of primary renal sarcomas in adult patients. Scientific Reports, May 2024. URL: https://doi.org/10.1038/s41598-024-60174-8, doi:10.1038/s41598-024-60174-8. This article has 7 citations and is from a peer-reviewed journal.

9. (mohd2022etiologiesgrossappearance pages 9-10): Ahmed B Mohd, Reem A Ghannam, Omar B Mohd, Rama Elayan, Khaled Albakri, Nesreen Huneiti, Farah Daraghmeh, Eman Al-khatatbeh, and Mohammad Al-thnaibat. Etiologies, gross appearance, histopathological patterns, prognosis, and best treatments for subtypes of renal carcinoma: an educational review. Cureus, Dec 2022. URL: https://doi.org/10.7759/cureus.32338, doi:10.7759/cureus.32338. This article has 24 citations.

10. (bradford2020primaryrenalewing pages 5-7): Kathryn Bradford, Alexander Nobori, Brittany Johnson, Wendy Allen-Rhoades, Bindi Naik-Mathuria, Eduard H. Panosyan, Moran Gotesman, Joseph Lasky, Jerry Cheng, Alan Ikeda, Jeffrey Goldstein, Arun Singh, and Noah Federman. Primary renal ewing sarcoma in children and young adults. Journal of Pediatric Hematology/Oncology, 42:474-481, Apr 2020. URL: https://doi.org/10.1097/mph.0000000000001804, doi:10.1097/mph.0000000000001804. This article has 24 citations.

Artifacts

• Edison artifact artifact-00

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Every term resolved, and every label the report gave matched.